他克莫司和重组人表皮生长因子凝胶在治疗糜烂型扁平苔藓中的效果观察与比较

发布时间：2018-04-02 01:31

  本文选题：口腔扁平苔藓　切入点：糜烂型口腔扁平苔藓　出处：《大连医科大学》2017年硕士论文

【摘要】：背景及目的:口腔扁平苔藓是一种常见的口腔黏膜慢性炎症疾病,其发病机制目前尚不明确,病损可同时累及皮肤和黏膜。其中糜烂型扁平苔藓因其经常在患者睡觉、进食、说话及其他的日常活动中出现疼痛,而对患者的生活造成严重的影响。有研究表明,用他克莫司来治疗糜烂型口腔扁平苔藓是安全并且有效的。重组人表皮生长因子凝胶可诱导细胞增殖、移行和分化,从而促进基底膜的形成,同时也可抑制T细胞的增殖。本实验的目的在于对比他克莫司与重组人表皮生长因子凝胶治疗糜烂型口腔扁平苔藓临床效果。方法:本实验的患者均来自大连医科大学附属第一医院口腔门诊。30名被口腔专科医生临床诊断为糜烂型口腔扁平苔藓的患者被随机分为三组,每组患者10名。A组给予他克莫司和白芍总苷胶囊;B组给予重组人表皮生长因子凝胶和白芍总苷胶囊;C组(对照组)给予氯己定漱口液及白芍总苷胶囊。在为期三个月的治疗期内,患者每月复诊一次,同时检查患者的疼痛程度、糜烂程度和病损面积的改变。结果:共有30名患者参与了此项试验,其中63%为女性患者、37%为男性,平均年龄51岁。在3个月的用药期内,A组和B组患者在疼痛程度的减轻方面无明显差异。A组和C组患者在疼痛程度的减轻方面有明显差异。B组和C组患者在疼痛程度的减轻方面有明显差异。在3个月的用药期内,A组和B组患者在糜烂程度减轻和病损面积缩小方面无明显差异。A组和C组患者在糜烂程度减轻和病损面积缩小方面有明显差异。B组和C组患者在糜烂程度减轻和病损面积缩小方面有明显差异。结论:在三个月的实验期内,他克莫司和重组人表皮生长因子凝胶均可减轻疼痛、减小病变范围。他克莫司和重组人表皮生长因子凝胶在减轻疼痛程度、和减小病损范围方面没有明显差异。
[Abstract]:Background & objective: oral lichen planus (OLP) is a common chronic inflammatory disease of oral mucosa. Pain in speech and other daily activities has a serious impact on the lives of patients. It is safe and effective to treat erosive oral lichen planus with tacrolimus. Recombinant human epidermal growth factor gel can induce cell proliferation, migration and differentiation, thus promoting the formation of basement membrane. The aim of this experiment was to treat erosive oral lichen planus with bitacrolimus and recombinant human epidermal growth factor gel. Methods: all patients in this study were from Dalian medicine. A total of 30 patients with erosive oral lichen planus (OLP) were randomly divided into three groups in the oral outpatient clinic of the first affiliated Hospital of the University of Science and Technology, which was clinically diagnosed as erosive oral lichen planus by an oral specialist. 10 patients in each group were given tacrolimus and total paeony glucoside capsule group B with recombinant human epidermal growth factor gel and total paeony glycoside capsule group C (control group) with chlorhexidine gargle and total paeony glycoside capsule. Within a month of treatment, The patients were reviewed once a month, and their pain, erosion and lesion area were examined. Results: a total of 30 patients participated in the study, 63 percent of whom were women and 37 percent of whom were men. The average age was 51 years. There was no significant difference in pain relief between group A and group B. there was a significant difference between group A and group C. there was a significant difference in pain between group B and group C. There was no significant difference in erosion degree and lesion area between group A and group B. there was no significant difference between group A and group C. patients in group A and group C reduced the degree of erosion and the area of lesion. There were significant differences between group B and group C. there were significant differences in erosive degree and lesion area between group B and group C. conclusion: during the three-month experimental period, there were significant differences between the two groups. Tacrolimus and recombinant human epidermal growth factor gel could reduce pain and lesion range, but tacrolimus gel and recombinant human epidermal growth factor gel had no significant difference in reducing pain and extent of lesion.
【学位授予单位】：大连医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R781.5
，

本文编号：1698207